Navidea highlights research on melanoma, oral cancer

2022 01 20 22 04 8815 Melanoma 400

Radiopharmaceutical developer Navidea Biopharmaceuticals is directing attention to new research from Australia on the use of its technetium-99m (Tc-99m) tilmanocept radiopharmaceutical in patients with melanoma or oral cancer.

Researchers from the University of Sydney prospectively assessed Tc-99m tilmanocept (also known as Lymphoseek) as a biomarker for lymphatic mapping and sentinel lymph node biopsy in 35 patients. They found that lymphoscintigraphy with Tc-99m tilmanocept identified at least one sentinel lymph node in all patients and enabled a 100% intraoperative retrieval rate of these lymph nodes in all patients.

What's more, imaging with Lymphoseek demonstrated 100% tissue specificity; lymph nodal tissue was confirmed histologically and there were no false positives, according to Navidea.

The study was published July 18 in the ANZ Journal of Surgery.

Page 1 of 435
Next Page